Skip to main content

Table 1 Patient clinical data

From: In vivo evolution of drug-resistant Mycobacterium tuberculosis in patients during long-term treatment

NO. Diagnosis DH(y) Weight loss(kg) HE Blood Chemistry ESR FC ID UB ARD OBI Survival
A IPT 45 9/64 (14.06%) N LAHTA, HCRP 11.37 ± 6.23 4.45 ± 1.23 No N RFP, PZA AHSC, NC YES
B CFPT 12 8/58 (13.79%) N NAHBA, HCRP 21.37 ± 8.23 6.45 ± 2.23 No N NO AHSC, NC YES
C IPT 28 17/75 (22.67%) N LAHBA, HCRP 35.38 ± 12 6.06 ± 1.60 No N NO AHSC, NC YES
D IPT 0 14/58 (24.13%) N NAHBA, HCRP 26.67 ± 2.52 5.64 ± 1.12 No N NO AHSC, NC YES
  1. DH(y) disease history (years), HE hematology, ESR erythrocyte sedimentation rate, FC fibrinogen concentration, ID immunodeficiency, UB urine biochemistry, ARD allergy reaction drugs, OBI other bacterial infection, IPT infiltrative pulmonary tuberculosis, CFPT chronic fibrocavenous pulmonary tuberculosis, LAHBA low alpha-hydroxybutyric acid, NAHBA normal alpha-hydroxybutyric acid, HCRP high C- reactive protein, AHSC α-hemolytic streptococcus, NC Neisser’s coccus, N normal